Associated Papers
Mathematical modeling of pharmacokinetics and pharmacodynamics of losartan in relation to CYP2C9 allele variants.
Babaev D et al.
Frontiers in Systems Biology, 2025
Pharmacogenomics of CYP2C9: Functional and Clinical Considerations.
Daly AK et al.
Journal of Personalized Medicine, 2017
Distribution of CYP2C8 and CYP2C9 amino acid substitution alleles in South Indian diabetes patients: A genotypic and computational protein phenotype study.
Rao DK et al.
Clinical and Experimental Pharmacology & Physiology, 2017
Pharmacogenomics of the cytochrome P450 2C family: impacts of amino acid variations on drug metabolism.
Isvoran A et al.
Drug Discovery Today, 2017
[POLYMORPHISM OF CYP2C9 GENE AND RISK OF HEPATOTOXICITY DEVELOPMENT DURING ANTIRETROVIRAL THERAPY.]
Kurbat MN et al.
Eksperimental'naia I Klinicheskaia Farmakologiia, 2016
Rise and fall of subclones from diagnosis to relapse in pediatric B-acute lymphoblastic leukaemia.
Ma X et al.
Nature Communications, 2015
25790293 (PubMed )
Supplement: ncomms7604-s3.xls › Sheet1
Warfarin pharmacogenetics.
Johnson JA et al.
Trends in Cardiovascular Medicine, 2015
Advances in molecular modeling of human cytochrome P450 polymorphism.
Martiny VY et al.
Journal of Molecular Biology, 2013
Polymorphic metabolism by functional alterations of human cytochrome P450 enzymes.
Lee IS et al.
Archives of Pharmacal Research, 2011
Contribution of CYP2C9 to variability in vitamin K antagonist metabolism.
Daly AK et al.
Expert Opinion on Drug Metabolism & Toxicology, 2006
Clinical consequences of cytochrome P450 2C9 polymorphisms.
Kirchheiner J et al.
Clinical Pharmacology and Therapeutics, 2005
Novel CYP2C9 genetic variants in Asian subjects and their influence on maintenance warfarin dose.
Zhao F et al.
Clinical Pharmacology and Therapeutics, 2004
Select a paper to view details